Literature DB >> 12753404

Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data.

Jürgen Bauer1, Claus Garbe.   

Abstract

Acquired melanocytic nevi (MN) in Caucasian populations are important markers for the risk of melanoma development. The total number of MN on the whole body is the most important independent risk factor for melanoma and the risk of melanoma development increases almost linearly with rising numbers of MN. Additionally, the presence of atypical MN and of actinic lentigines are likewise independent risk factors for melanoma. Atypical mole syndrome should be defined by the presence of many acquired MN and a threshold number of atypical MN. Acquired MN develops mainly during childhood and adolescence in the first two decades of life. The number of acquired nevi seems to be related to hereditary factors and nevus-prone families exist. The amount of sun exposure is the most important environmental risk factor for nevus development, particularly in early childhood. Interestingly, sunburns may play a role in nevus development, but seem not to be required, and even moderate sun exposure promotes the process. Therefore, preventive measures for nevus and melanoma development should target young children and adolescents.

Entities:  

Mesh:

Year:  2003        PMID: 12753404     DOI: 10.1034/j.1600-0749.2003.00047.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  30 in total

1.  [Taking responsibility for one's own health. Possibilities and limits using the example of malignant melanoma].

Authors:  G Marckmann; M Möhrle; A Blum
Journal:  Hautarzt       Date:  2004-08       Impact factor: 0.751

2.  Melanoma: A new strategy to reduce morbidity and mortality.

Authors:  Cameron Williams; Christopher Quirk; Anna Quirk
Journal:  Australas Med J       Date:  2014-07-31

3.  Melanoma survival in the United States, 1992 to 2005.

Authors:  Lori A Pollack; Jun Li; Zahava Berkowitz; Hannah K Weir; Xiao-Cheng Wu; Umed A Ajani; Donatus U Ekwueme; Chunyu Li; Brian P Pollack
Journal:  J Am Acad Dermatol       Date:  2011-11       Impact factor: 11.527

4.  Treatment of melanoma.

Authors:  Claus Garbe; Patrick Terheyden; Ulrich Keilholz; Oliver Kölbl; Axel Hauschild
Journal:  Dtsch Arztebl Int       Date:  2008-12-05       Impact factor: 5.594

Review 5.  Epidemiological and genetic factors underlying melanoma development in Italy.

Authors:  Giuseppe Palmieri; Maria Colombino; Milena Casula; Mario Budroni; Antonella Manca; Maria Cristina Sini; Amelia Lissia; Ignazio Stanganelli; Paolo A Ascierto; Antonio Cossu
Journal:  Melanoma Manag       Date:  2015-05-18

6.  Effect of hair color and sun sensitivity on nevus counts in white children in Colorado.

Authors:  Jenny Aalborg; Joseph G Morelli; Tim E Byers; Stefan T Mokrohisky; Lori A Crane
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

Review 7.  The etiology and molecular genetics of human pigmentation disorders.

Authors:  Laura L Baxter; William J Pavan
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012-05-17       Impact factor: 5.814

8.  Sunburn, sun exposure, and sun sensitivity in the Study of Nevi in Children.

Authors:  Jaya M Satagopan; Susan A Oliveria; Arshi Arora; Michael A Marchetti; Irene Orlow; Stephen W Dusza; Martin A Weinstock; Alon Scope; Alan C Geller; Ashfaq A Marghoob; Allan C Halpern
Journal:  Ann Epidemiol       Date:  2015-05-23       Impact factor: 3.797

9.  Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Authors:  Linda Gao; Karin van den Hurk; Peter T M Moerkerk; Jelle J Goeman; Samuel Beck; Nelleke A Gruis; Joost J van den Oord; Véronique J Winnepenninckx; Manon van Engeland; Remco van Doorn
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

Review 10.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.